By Robert Hand ([email protected]) As a health economist and outcomes researcher, you may work primarily within a single country. Naturally, you know the economic, regulatory, and management issues of that country. However, with globalisation, you need increasingly to be aware of the corresponding conditions around the world. Why? Individual countries or cooperative groups of countries…
Details
By Kevin Frick ([email protected]) It is ironic that we should have to answer the question: “what is the value of outcomes research?” when outcomes research is a key component of establishing the value of healthcare. Despite the seemingly obvious answer, i.e. “we could not possibly establish the value of healthcare without outcomes research”, there is…
Details
By Robert Hand ([email protected]) Under the title Legacy of Leadership, the American Medical Writers Association (AMWA) held its 67th Annual Conference on October 11–13 in Atlanta, Georgia. About 1000 medical communicators of all stripes attended. As always, AMWA offered a full programme of 95 certificate and non-certificate workshops, as well as 43 open sessions in…
Details
By David Woods ([email protected]) On January 1st 2006, Dr Dennis Gross retired from Merck after 28 years; the following day, he took up his present position as Associate Dean, Masters Programs, in the College of Graduate Studies at Thomas Jefferson University. At Merck, he had started out as a senior research pharmacologist working on the…
Details
Our HOC People person this month, Dennis M. Gross, PhD, is an associate dean at Thomas Jefferson University where he also teaches courses in pharmacology and toxicology. He emailed us these thoughts on non-adherence.
Details
By Mary Gabb ([email protected]) As we reported in last month’s HOC, the past few years have witnessed a surge of interest in the role of adherence in health economics research, highlighted by a recent report from the National Council on Patient Information and Education (NCPIE) in the United States, which revealed the high rates of…
Details
By David Woods ([email protected]) Writing in Pharmatech a couple of years ago, Dr Faiz Kermani observed that “many clinical trials are plagued by delays and setbacks that can cost pharmaceutical companies millions of dollars in missed sales, making the maximisation of R & D efforts a top priority.” It is not surprising, said Dr. Kermani,…
Details
By Ruth Whittington ([email protected]) The theme of this year’s ISPOR annual European Congress – the largest ever – was ‘Expanding Horizons’, and the Rx team took this very seriously, meeting almost every one of the 1700 delegates who visited our exhibition stand. The programme featured multiple workshops, podium presentations and forums. The first plenary session,…
Details
By David Woods ([email protected]) Entusiasmo. That’s a word that describes, in his native Italian, what Vittorio Maio brings to his work in health policy and outcomes research. “What makes me really happy,” he says, “is being able to see research theory translate into actual practice in the real world.” Vittorio graduated from the University of…
Details
By David Woods ([email protected]) Health clinics based in retail outlets, particularly drug stores, are changing the way primary care is delivered. Their proponents cite access, convenience, and price transparency as the major reasons for their popularity and growth. Further fueling this concept is the growing shortage of primary care doctors. Staffed mainly by nurse practitioners,…
Details